Compare HOOD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOOD | BMY |
|---|---|---|
| Founded | 2013 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.2B | 113.5B |
| IPO Year | 2021 | 2006 |
| Metric | HOOD | BMY |
|---|---|---|
| Price | $111.75 | $67.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 15 |
| Target Price | ★ $105.00 | $61.73 |
| AVG Volume (30 Days) | ★ 17.8M | 11.6M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | 31.41 | ★ 178.46 |
| EPS | 1.00 | ★ 2.93 |
| Revenue | $4,473,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $21.75 | N/A |
| Revenue Next Year | $19.35 | N/A |
| P/E Ratio | $103.62 | ★ $22.96 |
| Revenue Growth | ★ 51.58 | N/A |
| 52 Week Low | $63.52 | $42.52 |
| 52 Week High | $153.83 | $68.64 |
| Indicator | HOOD | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 64.35 |
| Support Level | $103.28 | $56.46 |
| Resistance Level | $121.76 | $68.10 |
| Average True Range (ATR) | 4.49 | 1.43 |
| MACD | 1.62 | 0.07 |
| Stochastic Oscillator | 81.31 | 77.93 |
Robinhood is a diversified financial services provider best known for its retail brokerage platform, which historically caters to a young, risk-seeking clientele that trades heavily on margin and in higher-risk asset classes like options, futures, cryptocurrencies, and more recently, in prediction markets. As those customers' financial needs have begun to mature, Robinhood has rolled out a suite of more conventional products, from retirement accounts to high-yield cash sweep accounts to nascent advisory services (Robinhood Strategies). With $322 billion in customer assets and 27 million active accounts at year-end 2025, the firm has emerged as a significant player in the large, growing US brokerage market.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.